搜索
Transcode Therapeutics Inc
RNAZ添加自选
7.207USD
+0.997+16.06%
交易中 （美东）报价延迟15分钟
6.61M总市值
亏损市盈率 TTM
关于 Transcode Therapeutics Inc 公司
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc简介
公司代码RNAZ
公司名称Transcode Therapeutics Inc
上市日期Apr 28, 2021
CEOCalais (Philippe P)
员工数量7
证券类型Ordinary Share
年结日Apr 28
公司地址6 Liberty Square
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02109
电话18573016857
网址https://www.transcodetherapeutics.com/
公司代码RNAZ
上市日期Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
常见问题
Transcode Therapeutics Inc的前五大股东是谁？
Transcode Therapeutics Inc 的前五大股东如下：Mr. Thomas A. (Tom) Fitzgerald
有多少机构持有Transcode Therapeutics Inc(RNAZ)的股份？
截至2026Q1，共有37家机构持有Transcode Therapeutics Inc的股份，合计持有的股份价值约为77.85K，占公司总股份的8.49%。与2025Q4相比，机构持股有所增加，增幅为-42306.00。